BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

...treat atopic dermatitis. Rinvoq is approved in the U.S. and Europe to treat rheumatoid arthritis. TG’s ublituximab...
...trialsTG Therapeutics Inc. (NASDAQ:TGTX) said the Phase III ULTIMATE I and ULTIMATE II studies of ublituximab...
BioCentury | May 6, 2020
Product Development

May 5 Quick Takes: Data propel Adverum, TG, Akebia stocks; plus Tolmar, SRI-Exscientia, Sino-GeoVax

...endpoint TG Therapeutics Inc. (NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab...
...growth factor VEGF-A - Vascular endothelial growth factor A BioCentury Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...He anticipates TG-1801 will have single-agent activity, but sees opportunities to combine the compound with ublituximab...
BioCentury | Jun 29, 2019
Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

...data 2H19 LFB S.A. / TG Therapeutics Inc. (NASDAQ:TGTX) / Ildong Pharmaceutical Co. Ltd. (KRX:000230) Ublituximab...
BioCentury | Sep 28, 2018
Clinical News

TG won't seek accelerated approval of CLL combo

...on Sept. 25 after the company said it will not seek accelerated approval of ublituximab (TG-1101...
...Rhizen Pharmaceuticals S.A., La Chaux-de-Fonds, Switzerland TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: Ublituximab (TG-1101...
...Phase III ongoing Milestone: Phase III data (2019); submit regulatory application (2019) Alicia Parker ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib...
BioCentury | Sep 25, 2018
Clinical News

TG won't seek accelerated approval of CLL combo; shares sink

...$5.15 on Tuesday after the company said it will not seek accelerated approval of ublituximab (TG-1101...
...more information about duration of response and safety. TG said UNITY-CLL's efficacy data remain blinded. Ublituximab...
...OTCQX:RHHBY) plus chlorambucil in both treatment-naïve and relapsed or refractory CLL patients. Alicia Parker ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib...
BioCentury | Jun 30, 2018
Finance

Eyes on launches

...date 9/16/18 TG Therapeutics Inc. (NASDAQ:TGTX) / Rhizen Pharmaceuticals S.A. Umbralisib (TGR-1202) and ublituximab (TG-1101, TGTX-1101...
BioCentury | Jun 8, 2018
Clinical News

TG Therapeutics reports Phase II data for umbralisib in CLL

...3-kinase (PI3K) delta inhibitors. Top-line data from the Phase III UNITY-CLL trial evaluating ublituximab (TG-1101, TGTX-1101...
...PI3K delta inhibitor, and ublituximab is a glycoengineered mAb against CD20. TG has rights to ublituximab...
BioCentury | Feb 9, 2018
Clinical News

TG reports updated Phase IIa MS data for anti-CD20 mAb

...sclerosis. Ublituximab is a glycoengineered mAb against CD20. Among 38 evaluable patients with relapsing MS, ublituximab...
...Patients received placebo or three infusions of IV ublituximab in one of five dose cohorts. Ublituximab...
...LFB S.A., Les Ulis, France TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: Ublituximab (TG-1101, TGTX-1101...
BioCentury | Feb 2, 2018
Clinical News

TG reports updated Phase IIa MS data for anti-CD20 mAb

...sclerosis. Ublituximab is a glycoengineered mAb against CD20. Among 38 evaluable patients with relapsing MS, ublituximab...
...baseline (p=0.0005). Among 40 evaluable patients, 97.5% of patients were relapse free at week 24. Ublituximab...
...Patients received placebo or three infusions of IV ublituximab in one of five dose cohorts. Ublituximab...
Items per page:
1 - 10 of 73